Business Wire

Mary Kay Unveils Skin Health Grants, Breakthrough Retinol Research at 2021 Society for Investigative Dermatology Conference

Share

Mary Kay Inc., a global leader in skin care innovation, continued its ongoing support of the beauty and scientific communities recently by sponsoring the virtual 2021 Society for Investigative Dermatology (SID) Annual Meeting, helping fund the society’s virtual meeting platform. At the meeting, Mary Kay unveiled breakthrough skin health research on a botanical extract reducing retinol-related irritation via the TRPV1 receptor. The brand was also excited to announce its first-ever grants for researchers conducting groundbreaking, innovative studies in skin health and skin disease.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005069/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mary Kay recently unveiled skin health grants and breakthrough research at the 2021 Society for Investigative Dermatology Conference.

Mary Kay will be awarding four $25,000 grants to researchers conducting groundbreaking and innovative studies in skin health or skin diseases, which eligible applicants can apply for through August 31, 2021. The winners of the Mary Kay grants will be announced at the SID annual meeting in 2022. Through the funds, Mary Kay hopes to empower researchers to uncover new perspectives and intervention strategies in the science of dermatology.

“Mary Kay is a firm believer that a collaborative effort is crucial in identifying new discoveries and innovation,” said Dr. Lucy Gildea, Mary Kay’s Chief Scientific Officer. “Events like the annual Society for Investigative Dermatology conference bring together the brightest minds working to advance the future of the field. May Kay is excited to be part of this scientific community, and we know these research grants will further help ongoing efforts in skin research. We are thrilled to see what scientists uncover next.”

Mary Kay’s own latest research explores the combination of retinol with a plant derived TRPV1 antagonist and anti-inflammatory botanical extract in mitigating retinoid-induced irritation. Using a cosmetic formulation, Mary Kay researchers were able to demonstrate gradual retinization over a period of eight weeks. Subjects who applied the formulation not only demonstrated high tolerability to the formulation, but also a reduction in dermatologist-assessed erythema, edema, and dryness after use.

“Our Research & Development team is consistently developing new skin care solutions for women around the world,” said Dr. Gildea. “Participating in events such as the SID annual meeting allows us to learn and share relevant research so we can continue to deliver meaningful benefits and amazing products to consumers.”

The Society of Investigative Dermatology Annual Meeting is just the latest event Mary Kay has participated in 2021 with scientific and academic communities that reinforce the brand’s long-standing commitment to advancing skin health research and development. Mary Kay holds more than 1,600 patents for products, technologies and packaging designs in its global portfolio.

ABOUT MARY KAY

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company 57 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press Release

Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process

FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release

The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th

Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release

Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor

Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release

Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not

BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye